Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6071-6083

  Cols, Montserrat ^a   Barra, Carolina M ^b   He, Bing ^a   Puga, Irene ^b   Xu, Weifeng ^a   Chiu, April ^c   Tam, Wayne ^d   Knowles, Daniel M ^d   Dillon, Stacey R ^e   Leonard, John P ^d   Furman, Richard R ^d   Chen, Kang ^a   Cerutti, Andrea ^a,b,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN RECEPTOR; CD40 ANTIGEN; CD40 LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; GENE; HUMAN; HUMAN CELL; IMMUNOGLOLUBIN GENE; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STROMA; UPREGULATION;

B-CELL ACTIVATING FACTOR; BLOTTING, SOUTHERN; CD40 LIGAND; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR CROSS-TALK; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STROMAL CELLS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84862627044     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102066     Document Type: Article

References (75)

1. Chiorazzi, N., K. R. Rai, and M. Ferrarini. 2005. Chronic lymphocytic leukemia. N. Engl. J. Med. 352: 804-815.
2. Damle, R. N., T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, et al. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847. (Pubitemid 29430399)
3. Hamblin, T. J., Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854. (Pubitemid 29430400)
4. Wiestner, A., A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis, S. E. Henrickson, H. Zhao, R. E. Ibbotson, J. A. Orchard, Z. Davis, et al. 2003. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951. (Pubitemid 36857758)
5. Furman, R. R., Z. Asgary, J. O. Mascarenhas, H. C. Liou, and E. J. Schattner. 2000. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164: 2200-2206. (Pubitemid 30108780)
6. Grubor, V., A. Krasnitz, J. E. Troge, J. L. Meth, B. Lakshmi, J. T. Kendall, B. Yamrom, G. Alex, D. Pai, N. Navin, et al. 2009. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 113: 1294-1303.
7. Fais, F., F. Ghiotto, S. Hashimoto, B. Sellars, A. Valetto, S. L. Allen, P. Schulman, V. P. Vinciguerra, K. Rai, L. Z. Rassenti, et al. 1998. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102: 1515-1525. (Pubitemid 28492218)
8. Chiorazzi, N., and M. Ferrarini. 2003. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21: 841-894. (Pubitemid 37174549)
9. Murray, F., N. Darzentas, A. Hadzidimitriou, G. Tobin, M. Boudjogra, C. Scielzo, N. Laoutaris, K. Karlsson, F. Baran-Marzsak, A. Tsaftaris, et al. 2008. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111: 1524-1533. (Pubitemid 351213442)
10. Caligaris-Cappio, F., and P. Ghia. 2008. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J. Clin. Oncol. 26: 4497-4503.
11. Herishanu, Y., P. Pérez-Galán, D. Liu, A. Biancotto, S. Pittaluga, B. Vire, F. Gibellini, N. Njuguna, E. Lee, L. Stennett, et al. 2011. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117: 563-574.
12. Burger, J. A., M. Burger, and T. J. Kipps. 1999. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94: 3658-3667.
13. Nishio, M., T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. C. Reed, N. J. Zvaifler, and T. J. Kipps. 2005. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 106: 1012-1020. (Pubitemid 41076448)
14. Bürkle, A., M. Niedermeier, A. Schmitt-Gräff, W. G. Wierda, M. J. Keating, and J. A. Burger. 2007. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110: 3316- 3325.
15. Litinskiy, M. B., B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3: 822-829.
16. He, B., W. Xu, P. A. Santini, A. D. Polydorides, A. Chiu, J. Estrella, M. Shan, A. Chadburn, V. Villanacci, A. Plebani, et al. 2007. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelialcell secretion of the cytokine APRIL. Immunity 26: 812-826. (Pubitemid 46915505)
17. Xu, W., B. He, A. Chiu, A. Chadburn, M. Shan, M. Buldys, A. Ding, D. M. Knowles, P. A. Santini, and A. Cerutti. 2007. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat. Immunol. 8: 294-303. (Pubitemid 46745379)
18. Chen, K., W. Xu, M. Wilson, B. He, N. W. Miller, E. Bengtén, E. S. Edholm, P. A. Santini, P. Rath, A. Chiu, et al. 2009. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol. 10: 889-898.
19. Mackay, F., and P. Schneider. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9: 491-502.
20. Cerutti, A., I. Puga, and M. Cols. 2011. Innate control of B cell responses. Trends Immunol. 32: 202-211.
21. Puga, I., M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A. Chorny, M. Shan, W. Xu, et al. 2012. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 13: 170-180.
22. Cerutti, A., K. Chen, and A. Chorny. 2011. Immunoglobulin responses at the mucosal interface. Annu. Rev. Immunol. 29; 273-293.
23. Schattner, E. J., J. Mascarenhas, I. Reyfman, M. Koshy, C. Woo, S. M. Friedman, and M. K. Crow. 1998. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 91: 2689-2697. (Pubitemid 28227517)
24. Ghia, P., G. Strola, L. Granziero, M. Geuna, G. Guida, F. Sallusto, N. Ruffing, L. Montagna, P. Piccoli, M. Chilosi, and F. Caligaris-Cappio. 2002. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 32: 1403-1413. (Pubitemid 34546268)
25. Chen, H., A. T. Treweeke, D. C. West, K. J. Till, J. C. Cawley, M. Zuzel, and C. H. Toh. 2000. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96: 3181-3187.
26. Buggins, A. G., C. Pepper, P. E. Patten, S. Hewamana, S. Gohil, J. Moorhead, N. Folarin, D. Yallop, N. S. Thomas, G. J. Mufti, et al. 2010. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 70: 7523-7533.
27. Cheson, B. D., J. M. Bennett, M. Grever, N. Kay, M. J. Keating, S. O'Brien, and K. R. Rai. 1996. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997. (Pubitemid 26189840)
28. Cerutti, A., A. Schaffer, S. Shah, H. Zan, H. C. Liou, R. G. Goodwin, and P. Casali. 1998. CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity 9: 247-256. (Pubitemid 28400038)
29. He, B., R. Santamaria, W. Xu, M. Cols, K. Chen, I. Puga, M. Shan, H. Xiong, J. B. Bussel, A. Chiu, et al. 2010. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat. Immunol. 11: 836-845.
30. Lee, Y. K., N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay. 2004. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104: 788-794. (Pubitemid 38970575)
31. Lee, Y. K., T. D. Shanafelt, N. D. Bone, A. K. Strege, D. F. Jelinek, and N. E. Kay. 2005. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 19: 513-523. (Pubitemid 40521153)
32. Cerutti, A., H. Zan, E. C. Kim, S. Shah, E. J. Schattner, A. Schaffer, and P. Casali. 2002. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J. Immunol. 169: 6594-6603. (Pubitemid 36903513)
33. Palacios, F., P. Moreno, P. Morande, C. Abreu, A. Correa, V. Porro, A. I. Landoni, R. Gabus, M. Giordano, G. Dighiero, et al. 2010. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 115: 4488-4496.
34. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
35. Albesiano, E., B. T. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, and N. Chiorazzi. 2003. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 102: 3333-3339. (Pubitemid 37314775)
36. Oppezzo, P., F. Vuillier, Y. Vasconcelos, G. Dumas, C. Magnac, B. Payelle- Brogard, O. Pritsch, and G. Dighiero. 2003. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood 101: 4029-4032. (Pubitemid 36857882)
37. Guikema, J. E., S. Rosati, K. Akkermans, R. J. Bende, C. J. van Noesel, J. H. van Krieken, M. L. Hansmann, E. Schuuring, and P. M. Kluin. 2005. Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients. Blood 105: 2997-2998, discussion 2998-2999.
38. Deaglio, S., A. Capobianco, L. Bergui, J. Dürig, F. Morabito, U. Dührsen, and F. Malavasi. 2003. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102: 2146-2155. (Pubitemid 37122392)
39. Deaglio, S., T. Vaisitti, L. Bergui, L. Bonello, A. L. Horenstein, L. Tamagnone, L. Boumsell, and F. Malavasi. 2005. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105: 3042-3050.
40. Damle, R. N., S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi. 2007. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352-3359. (Pubitemid 350106329)
41. Patten, P. E., A. G. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux. 2008. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111: 5173-5181.
42. Novak, A. J., R. J. Bram, N. E. Kay, and D. F. Jelinek. 2002. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100: 2973-2979.
43. Kern, C., J. F. Cornuel, C. Billard, R. Tang, D. Rouillard, V. Steunou, T. Defrance, F. Ajchenbaum-Cymbalista, P. Y. Simonin, S. Feldblum, and J. P. Kolb. 2004. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-688. (Pubitemid 38145555)
44. He, B., A. Chadburn, E. Jou, E. J. Schattner, D. M. Knowles, and A. Cerutti. 2004. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 172: 3268-3279. (Pubitemid 38263719)
45. Endo, T., M. Nishio, T. Enzler, H. B. Cottam, T. Fukuda, D. F. James, M. Karin, and T. J. Kipps. 2007. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 109: 703-710. (Pubitemid 46105972)
46. Zhang, W., A. P. Kater, G. F. Widhopf, II, H. Y. Chuang, T. Enzler, D. F. James, M. Poustovoitov, P. H. Tseng, S. Janz, C. Hoh, et al. 2010. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 107: 18956-18960.
47. Novak, A. J., J. R. Darce, B. K. Arendt, B. Harder, K. Henderson, W. Kindsvogel, J. A. Gross, P. R. Greipp, and D. F. Jelinek. 2003. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103: 689-694.
48. Novak, A. J., D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, et al. 2004. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104: 2247-2253. (Pubitemid 39331819)
49. Chiu, A., W. Xu, B. He, S. R. Dillon, J. A. Gross, E. Sievers, X. Qiao, P. Santini, E. Hyjek, J. W. Lee, et al. 2007. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109: 729-739. (Pubitemid 46105975)
50. Mackay, F., and S. G. Tangye. 2004. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr. Opin. Pharmacol. 4: 347-354. (Pubitemid 38987060)
51. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16: 111-135. (Pubitemid 28183361)
52. He, B., N. Raab-Traub, P. Casali, and A. Cerutti. 2003. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J. Immunol. 171: 5215-5224. (Pubitemid 37432806)
53. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756. (Pubitemid 29272691)
54. López-Fraga, M., R. Fernández, J. P. Albar, and M. Hahne. 2001. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2: 945-951. (Pubitemid 33040585)
55. Bossen, C., A. Tardivel, L. Willen, C. A. Fletcher, M. Perroud, F. Beermann, A. G. Rolink, M. L. Scott, F. Mackay, and P. Schneider. 2011. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur. J. Immunol. 41: 787-797.
56. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733. (Pubitemid 27098094)
57. Messmer, B. T., D. Messmer, S. L. Allen, J. E. Kolitz, P. Kudalkar, D. Cesar, E. J. Murphy, P. Koduru, M. Ferrarini, S. Zupo, et al. 2005. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115: 755-764. (Pubitemid 40322252)
58. Calissano, C., R. N. Damle, G. Hayes, E. J. Murphy, M. K. Hellerstein, C. Moreno, C. Sison, M. S. Kaufman, J. E. Kolitz, S. L. Allen, et al. 2009. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114: 4832-4842.
59. Chu, C. C., R. Catera, K. Hatzi, X. J. Yan, L. Zhang, X. B. Wang, H. M. Fales, S. L. Allen, J. E. Kolitz, K. R. Rai, and N. Chiorazzi. 2008. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112: 5122-5129.
60. Burger, J. A., N. Tsukada, M. Burger, N. J. Zvaifler, M. Dell'Aquila, and T. J. Kipps. 2000. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96: 2655-2663.
61. Pedersen, I. M., S. Kitada, L. M. Leoni, J. M. Zapata, J. G. Karras, N. Tsukada, T. J. Kipps, Y. S. Choi, F. Bennett, and J. C. Reed. 2002. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100: 1795-1801. (Pubitemid 34925159)
62. Gattei, V., P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al. 2008. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111: 865-873.
63. Gorelik, L., K. Gilbride, M. Dobles, S. L. Kalled, D. Zandman, and M. L. Scott. 2003. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 198: 937-945. (Pubitemid 37152930)
64. Dole, V. S., W. Bergmeier, H. A. Mitchell, S. C. Eichenberger, and D. D. Wagner. 2005. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 106: 2334-2339. (Pubitemid 41510804)
65. Do, R. K., E. Hatada, H. Lee, M. R. Tourigny, D. Hilbert, and S. Chen-Kiang. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192: 953-964.
66. Schneider, P. 2005. The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 17: 282-289. (Pubitemid 40692663)
67. Dillon, S. R., J. A. Gross, S. M. Ansell, and A. J. Novak. 2006. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 5: 235-246. (Pubitemid 43336036)
68. Moreaux, J., A. C. Sprynski, S. R. Dillon, K. Mahtouk, M. Jourdan, A. Ythier, P. Moine, N. Robert, E. Jourdan, J. F. Rossi, and B. Klein. 2009. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur. J. Haematol. 83: 119-129.
69. Hildebrand, J. M., Z. Luo, M. K. Manske, T. Price-Troska, S. C. Ziesmer, W. Lin, B. S. Hostager, S. L. Slager, T. E. Witzig, S. M. Ansell, et al. 2010. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J. Exp. Med. 207: 2569-2579.
70. Mihalcik, S. A., R. C. Tschumper, and D. F. Jelinek. 2010. Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle 9: 4884-4892.
71. Pham, L. V., L. Fu, A. T. Tamayo, C. Bueso-Ramos, E. Drakos, F. Vega, L. J. Medeiros, and R. J. Ford. 2011. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. Blood 117: 200-210.
72. Avery, D. T., S. L. Kalled, J. I. Ellyard, C. Ambrose, S. A. Bixler, M. Thien, R. Brink, F. Mackay, P. D. Hodgkin, and S. G. Tangye. 2003. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112: 286-297. (Pubitemid 38056364)
73. O'Connor, B. P., V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L. L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199: 91-98.
74. Moreaux, J., E. Legouffe, E. Jourdan, P. Quittet, T. Rème, C. Lugagne, P. Moine, J. F. Rossi, B. Klein, and K. Tarte. 2004. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157. (Pubitemid 38451693)
75. Okazaki, I. M., A. Kotani, and T. Honjo. 2007. Role of AID in tumorigenesis. Adv. Immunol. 94: 245-273. (Pubitemid 46856613)